Aptitude Receives up to $54 Million Partnership with BARDA to Develop Diagnostics for Point-of-Care and At-Home Use
SANTA BARBARA, Calif., April 20, 2023 /PRNewswire/ -- Aptitude Medical Systems (Aptitude™) announced today that it has received an award up to $53.7 million from Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The funding supports the development of over-the-counter molecular diagnostics capable of delivering lab-quality results in 15-30 minutes while approaching the cost of antigen tests.
- The funding supports the development of over-the-counter molecular diagnostics capable of delivering lab-quality results in 15-30 minutes while approaching the cost of antigen tests.
- The Metrix COVID-19 Test is the first product on the Metrix platform and received Emergency Use Authorization from the FDA [ https://www.fda.gov/news-events/press-announcements/fda-roundup-october-... ].
- It will be closely followed by the Metrix COVID/Flu Test and software to integrate patient, providers, payers, and public health.
- Aptitude aims to make molecular tests as accessible as antigen tests according to JP Wang, PhD, Aptitude CSO and co-founder.